As per Electrive, R44 and R66 are the models that will pave the way towards the development of the upcoming hydrogen models, which will be used by medical institutions that transport organs for transplants. The development has two main objectives, accelerating the development of net-zero aircraft, as well as simplifying the process of regulatory approvals for future models.

The California-based helicopter manufacturer will contribute in the deal with its expertise on building the aircraft, as well as taking care of the regulatory approvals necessary for bringing the final product on the market. UB will use the future aircraft to complete organ transports between medical units.

Lung Biotechnology, a subsidiary of UB already employs electric R44 helicopters, which have been converted using batteries and hydrogen fuel cells will extend the range of these models.

David Smith, President and CEO of Robinson Helicopter Company, said that "by deepening our existing relationship with Unither Bioelectronics, we can accelerate the arrival of zero-emission helicopters."

Mikael Cardinal, Vice President of Program Management and Organ Delivery Systems and head of the United Therapeutics Organ Delivery Systems (UTODS) development program, said that "hydrogen-powered aircraft are the next frontier in sustainable aviation. We are committed to developing a zero-operational carbon emission fleet of aircraft, and we look forward to working with the expert team at Robinson Helicopter to enable regulatory approval and production of these aircraft."